-
TreeFrog Therapeutics and Invetech started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology to enable the mass production of hPSC-derived cell therapies in industrial bioreactors, with best-in-class cell quality and low production costs.
-
Invetech delivered a beta encapsulation system with a throughput of 1,000 stem cell capsules per second to TreeFrog Therapeutics in the second quarter of 2020.
-
The strategic partnership aims to develop a GMP-compliant encapsulation device by the end of 2022 to support TreeFrog Therapeutics’ in-house and partnered cell therapy programs.
FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin(TM)
Miami, FL (September 29, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19. [Read more…]
Ronawk Offering Free Samples of T-Blocks to Slash Stem Cell Expansion Costs & Labor Hours
OLATHE, Kansas — Ronawk, innovators in stem cell expansion technologies, has launched a trial program to provide its patented tissue-blocks (T-Blocks) to commercial cell producers and regenerative medicine partners. Their T-Blocks are a 3D matrix consumable product that enable the stem cell industry by providing means to increase stem cell production by 3,600 times vs. traditional expansion methods. [Read more…]
Three New COVID-19 Patients Treated with Zofin(TM) Report Improvement
Organicell Commences Phase I/II Clinical Trial Enrollment
Miami, FL (September 2, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient. [Read more…]
denovoMATRIX GmbH on the path to enabling cell-based therapies
Now awarded ISO 9001:2015 Certification for Quality Management System
As an organization, denovoMATRIX is driven by the undertaking of continuous improvement of our quality management system, a commitment to unremitting development of our staff and the fostering of customer relationships. denovoMATRIX GmbH is pleased to announce its ISO 9001:2015 Quality Management Standard certification by TÜV Süd. [Read more…]
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 97
- Next Page »